ArdorComm Media News Network
November 6, 2026
The Union Health Ministry has proposed changes to the Drugs Rules, 1945, that would allow authorities to immediately suspend the manufacturing licences of pharmaceutical companies producing medicines that fail to meet specified critical quality standards.
The proposed amendments, announced on November 4, 2026, aim to strengthen drug quality monitoring, enable faster regulatory action against substandard medicines and prevent potentially unsafe products from remaining in circulation.
Under the existing rules, suspension or cancellation of a drug manufacturing licence generally involves a prescribed regulatory process, including the issuance of a show-cause notice. This can create a delay between the identification of a Not of Standard Quality (NSQ) drug and the initiation of action, during which the medicine may continue to be available in the market.
To address this gap, the ministry has proposed empowering the Central Licensing Approving Authority or the concerned State Licensing Authority to immediately suspend a drug’s manufacturing licence after receiving a Government Analyst’s report declaring it NSQ on specified parameters.
These include assay, dissolution, related substances, impurities and sterility. According to the ministry, failures involving these parameters can directly affect medicine quality and patient safety, requiring immediate regulatory intervention.
Manufacturers must implement corrective measures
The proposed framework also specifies conditions for revoking a suspension. Manufacturers will be required to conduct a comprehensive root cause analysis to identify the reasons behind the quality failure and implement appropriate Corrective and Preventive Action (CAPA).
The suspension will remain in force until the licensing authority is satisfied that the necessary corrective measures have been implemented and verified. This is intended to ensure that quality deficiencies are properly addressed and measures are taken to prevent similar failures in the future.
The ministry has also proposed changes to Form 13, which covers Government Analyst test reports, to improve communication and coordination among regulatory authorities and industry stakeholders.
Under the revised mechanism, copies of NSQ reports will be sent to the Drugs Controller General of India (DCGI), the relevant State or Union Territory Licensing Authority overseeing the manufacturing facility, and the manufacturer and marketer of the concerned medicine.
The government said the arrangement would facilitate faster information sharing, coordinated regulatory action and greater accountability across the pharmaceutical manufacturing and distribution chain.
Draft amendments open for public consultation
The proposed changes follow discussions at the 65th meeting of the Drugs Consultative Committee held on December 20, 2024, and recommendations made during the 92nd meeting of the Drugs Technical Advisory Board on April 24, 2025.
The amendments are expected to improve post-marketing drug surveillance, strengthen action against manufacturers of substandard medicines and enhance accountability among pharmaceutical companies and marketers.
The draft rules have been released for public consultation. Stakeholders and members of the public can submit their objections and suggestions within 30 days from the date on which the relevant Gazette of India notification becomes available.
Source: The Hindu